Tapticom - Instructions For The Use Of Eye Drops, Price, Reviews, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Tapticom

Tapticom: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Use in the elderly
14. 14. Drug interactions
15. 15. Analogs
16. 16. Terms and conditions of storage
17. 17. Terms of dispensing from pharmacies
18. 18. Reviews
19. 19. Price in pharmacies

Latin name: Tapticom

ATX code: S01EE05; S01ED51

Active ingredient: tafluprost (Tafluprost) + timolol (Timolol)

Manufacturer: Laboratoire Unither (France)

Description and photo update: 2020-23-01

Prices in pharmacies: from 852 rubles.

Buy

Tapticom is a combined antiglaucoma drug.

Release form and composition

Dosage form - eye drops (0.0015% + 0.5%): colorless transparent solution (0.3 ml each in polyethylene dropper tubes for single use, 5 dropper tubes are soldered into one strip, in bags of aluminum coated paper - 2 strips are packed in polyethylene foil; in a cardboard box 3 or 9 bags and instructions for use of Tapticom).

Composition for 1 ml of the preparation:

• active ingredients: tafluprost - 0.015 mg; timolol - 5 mg (in the form of timolol maleate - 6.84 mg);
• auxiliary ingredients: polysorbate 80 - 0.75 mg; disodium edetate - 0.5 mg; disodium hydrogen phosphate - 4.9 mg; glycerol - 22.5 mg; sodium hydroxide - 0.04-0.06 mg or hydrochloric acid - 0-0.2 mg to bring the pH to normal; water for injection - up to 1 ml.

Pharmacological properties

Pharmacodynamics

Eye drops Tapticom contain a fixed combination of tafluprost and timolol - two active components that reduce intraocular pressure (IOP). They demonstrate synergism, mutually reinforcing the action of each other, from which the decrease in IOP due to the use of the combined preparation is more pronounced than with the action of each of the substances separately.

Active substances in Tapticom:

• tafluprost: a fluorinated synthetic analogue of prostaglandin F _2α, the biologically active metabolite of which (tafluprostic acid) exhibits high activity and selectivity towards human prostaglandin F _2α receptors (FP receptors). In preclinical studies to study the pharmacodynamics of tafluprost, it was determined that its IOP-lowering action occurs due to an increase in the uveoscleral outflow of aqueous humor;
• timolol maleate: a non-selective β-blocker, the exact mechanism for lowering IOP is currently not fully understood. Methods of tonography and fluorescence, however, indicate that the main effect may be due to inhibition of the synthesis of intraocular fluid. In some studies, at the same time, a slight increase in its outflow was noted.

The use of Tapticom for the treatment of ophthalmic hypertension or open-angle glaucoma in patients with an average IOP of 24–26 mm Hg before therapy. Art., provided a decrease in this indicator not lower than the combined use of tafluprost 0.0015% with timolol 0.5%. Six months later, the decrease in the average daily IOP was 8 mm Hg. Art. from the original value.

Along with this, studies were conducted comparing the activity of Tapticom and the corresponding monotherapy agents in patients with ophthalmic hypertension or open-angle glaucoma, whose average IOP before treatment was 26–27 mm Hg. Art. It was confirmed that the average daily IOP during therapy with Tapticom was statistically more significant than that as a result of monotherapy with tafluprost (1 time per day, in the morning) or timolol (2 times a day). After 3 months of observation in the Tapticom group, the decrease in the average daily IOP to the initial level was 9 mm Hg. Art., in both groups of monotherapy - 7 mm Hg. Art. In the patients who used Tapticom, the decrease in IOP during the day ranged from 7 to 9 mm Hg. Art.

Pooled results from two clinical trials (n = 168) in patients with baseline high IOP ≥ 26 mm Hg. Art. showed that with Tapticom therapy after 3 or 6 months, the average daily decrease in IOP was 10 mm Hg. Art. (daily range 9–12 mm Hg).

Pharmacokinetics

Pharmacokinetic characteristics of tafluprost:

• absorption: the plasma concentration of tafluprost acid in the blood of healthy volunteers was determined both after a single use and after repeated use for 8 days of eye drops Tapticom (1 time per day), as well as tafluprost 0.0015% (1 time per day) and timolol 0, 5% (2 times a day). It was revealed that T _Cmax is the time to reach the maximum concentration (C _max) - tafluprostic acid in blood plasma for Tapticom is 10 minutes, within about half an hour its level decreases below the sensitivity threshold of the analysis method, which is 10 pg / ml. The accumulation of the active metabolite tafluprost was insignificant. On the 8th day, the average values of the area under the "concentration - time" curve from drug administration to the determination of the last quantifiable concentration (AUC _0-last) with monotherapy were 4.45 ± 2.57 pg / ml per hour, with Tapticom treatment - 3.6 ± 3.7 pg / ml per hour; level C _maxrespectively equal to 23.9 ± 11.8 pg / ml and 18.7 ± 11.9 pg / ml. In the case of using the drug, the values were slightly lower than with tafluprost monotherapy. Tafluprost is absorbed through the cornea, preclinical studies have shown that its absorption when taking Tapticom is comparable to penetration when monotherapy with tafluprost 1 time per day. The AUC value of _{0-4 hours of} tafluprost acid after instillation of Tapticom and tafluprost monopreparation was 7.5 ng / ml per hour and 7.7 ng / ml per hour, respectively; the maximum time (T _max) of the therapeutic doses of the substance in the plasma in both cases is 1 hour;
• distribution: radioisotope-labeled tafluprost (³ H-tafluprost), when distributed in the tissues of the eye, shows a low affinity for the melanin pigment; the results of autoradiographic studies showed that the maximum level of radioactivity was observed in the cornea, then in the eyelids, the shell of the eyeball and the iris. In other organs, radioactively labeled tafluprost was distributed as the concentration decreased as follows: the lacrimal gland and lacrimal passages, palate, esophagus, gastrointestinal tract, kidneys, liver, urinary and gall bladders. At a concentration of tafluprostic acid of 500 ng / ml, its binding to human serum albumin in vitro was 99%;
• metabolism: in vitro, the main pathway of biotransformation of tafluprost is confirmed - hydrolysis, as a result of which a pharmacologically active metabolite, tafluprostic acid, is formed, which is further converted by glucuronization or β-oxidation. During β-oxidation, pharmacologically inactive 1,2-dinor- and 1,2,3,4-tetranortafluprostic acids are formed, which subsequently undergo glucuronidation or hydroxylation. The enzyme system of cytochrome P ₄₅₀ does not participate in the metabolism of tafluprost. Studies carried out on the tissues of the cornea of a rabbit using refined enzymes revealed that the main esterase responsible for the ester hydrolysis of tafluprost to tafluprost acid is carboxylesterase; in addition to it, butyrylcholinesterase can also promote hydrolysis;
• excretion: in studies conducted on rats, after instillation of 0.005% ophthalmic solution of radioactive ³ H-tafluprost once a day in both eyes for 3 weeks, it was found that up to 87% of the total radioactive dose is excreted through excretory organs, incl. about 27–38% of the total dose was excreted by the kidneys, and about 44–58% through the gastrointestinal tract.

Pharmacokinetic characteristics of timolol:

• absorption: the plasma concentration of thymolic acid in the blood of healthy volunteers was determined after a single and repeated use for 8 days of eye drops Tapticom (1 time per day), as well as tafluprost 0.0015% (1 time per day) and timolol 0.5% (2 times a day). It was found that the level of timolol in blood plasma after instillation of Tapticom on the 1st and 8th days reached a maximum after 15 minutes and 37.5 minutes, respectively (median T _max). On the eighth day, the AUC _0-last value of timolol with monotherapy was 5750 ± 2440 pg / ml per hour, with treatment with Tapticom - 4560 ± 2980 pg / ml per hour; mean value C _maxrespectively, was 1100 ± 550 pg / ml and 840 ± 520 pg / ml. The rates with the use of Tapticom were slightly lower than those with monotherapy with timolol, which is understandable, since Tapticom is instilled once a day, and timolol with monotherapy - 2 times. Timolol is absorbed through the cornea, preclinical studies have shown that its absorption after taking Tapticom is slightly lower than with monotherapy. The AUC value of _{0-4 hours of} timolol after instillation of Tapticom and the monopreparation was, respectively, 585 ng / ml per hour and 737 ng / ml per hour. T _{max of} timolol is 1 hour after instillation of Tapticom and 0.5 hours with timolol alone;
• distribution: according to the data of preclinical studies labeled with a radioisotope ³ N timolol, C _max in aqueous humor is achieved half an hour after its single use in the form of a 0.5% solution (20 μl / eye); timolol is excreted from aqueous humor much faster than from the tissues of the iris containing pigment and the ciliary body;
• metabolism: biotransformation of timolol occurs in the liver with the participation of the isoenzyme CYP2D6 of cytochrome P ₄₅₀, as a result of which inactive metabolites are formed, subject mainly to renal elimination;
• excretion (data on excretion were obtained with oral administration of timolol): the expected half-life (T _1/2) from blood plasma is ~ 4 hours; timolol is excreted in the urine, most in the form of metabolites, about 20% is excreted unchanged.

Indications for use

Tapticom is recommended to be used to reduce IOP in open-angle glaucoma or ophthalmic hypertension in adult patients in case of insufficient response to local use of drugs of the β-blocker group or prostaglandin analogs, when combined treatment is indicated.

Taptic is also prescribed to patients who are expected to improve its tolerance due to the instillation of preservative-free eye drops.

Contraindications

Absolute:

• pulmonary pathologies: severe COPD (chronic obstructive pulmonary disease), increased airway reactivity, including bronchial asthma or a history of it;
• diseases of the cardiovascular system: sinus bradycardia, SSS (sick sinus syndrome), sinoatrial blockade, AV (atrioventricular) blockade of II and III degrees without a pacemaker, cardiogenic shock, heart failure in the phase of decompensation;
• children and adolescents up to 18 years of age (no data on clinical use);
• pregnancy and breastfeeding;
• hypersensitivity to tafluprost, timolol, or any of the auxiliary components of the drug.

Due to the limited experience of using Tapticom eye drops in some groups of patients, it is recommended to use them with caution in hepatic / renal failure; eye pathologies - aphakia, pseudophakia (in case of rupture of the posterior lens capsule or implantation of the lens into the anterior chamber of the eye), pseudoexfoliative / pigmentary glaucoma, with established risk factors for the development of iritis / uveitis or cystic macular edema, patients with neovascular / closed-angle / narrow-angle / narrow-angle / (in this patient population, there is no experience with tafluprost), with corneal diseases that can cause dry eye syndrome; cardiovascular diseases - ischemic heart disease (ischemic heart disease), Prinzmetal angina pectoris, heart failure, AV blockade of the 1st degree,peripheral circulatory disorders (severe forms of Raynaud's disease / syndrome); COPD of mild to moderate severity (use is possible if the expected benefit outweighs the potential risks); labile course of diabetes mellitus or spontaneous hypoglycemia (since β-blockers are capable of masking clinical signs and symptoms of acute hypoglycemia); concomitant treatment with β-blockers (both with oral administration and in the form of ocular instillations).and in the form of eye instillations).and in the form of eye instillations).

Tapticom, instructions for use: method and dosage

Eye drops Tapticom are intended for ophthalmic use only.

The recommended (maximum allowable) dose is once a day 1 drop of the solution into the conjunctival sac of the affected eye or eyes.

You should not exceed the recommended daily dose of Tapticom, since more frequent use of drops may worsen the expected effect of lowering IOP.

If the current dose is skipped, therapy is continued with the next scheduled instillation.

Tapticom is a sterile solution without preservatives, packaged in a disposable dropper tube. One dropper tube contains a volume of solution that is sufficient exclusively for a single instillation in both eyes.

To reduce the risk of eyelid skin pigmentation when instilling the solution, it is necessary to remove excess from the skin.

As in the case of instillation of other eye drops, during short-term pressing with fingers of the nasolacrimal canals or when closing the eyelids for 2 minutes after instillation, the systemic absorption of the drug decreases. This reduces the likelihood of developing systemic adverse reactions and enhances the local effect of the solution.

When using several topical ophthalmic agents, intervals of at least 5 minutes must be observed between their use.

Contact lenses are removed before instillation, they can be put on again 15 minutes after the procedure.

Patients should be warned that touching the eye and surrounding tissues with the tip of the dropper tube may damage them.

The dropper tube after a single use is disposed of together with the rest of the solution.

Failure to comply with the rules for storing ophthalmic preparations significantly increases the risk of bacterial contamination. This can cause the development of bacterial infection of the organ of vision, which can lead to a significant deterioration in visual function or to loss of vision.

Side effects

In a clinical study of Tapticom involving more than 484 volunteers, the side effect associated with therapy most often (up to 7%) was hyperemia of the mucous membrane of the eye, mostly mild. Other adverse reactions were consistent with those previously observed with the separate use of tafluprost and timolol. No new side effects characteristic only of Tapticom were found in the course of clinical trials. In most cases, adverse reactions from the organ of vision were mild or moderate; serious negative effects were not recorded.

When assessing the frequency of adverse actions Tapticom used the following scale: very often - not less than 0.1 cases; often - not less than 0.01 and less than 0.1; infrequently - not less than 0.001 and less than 0.01; rarely - not less than 0.0001 and less than 0.001; extremely rare - less than 0.000 01; unknown - frequency cannot be determined from available observational data.

Undesirable side reactions from systems and organs registered with the use of Tapticom (combination of tafluprost and timolol):

• nervous system: infrequently - headache;
• organ of vision: often - hyperemia of the mucous membrane of the eye, itching / pain in the eyes, changes in the appearance of eyelashes (increase in thickness, length and number, change in pigmentation), sensation of a foreign body in the eye, eye irritation, blurred vision, photophobia; infrequently - dryness of the conjunctiva of the eye, discomfort around the eyes, discomfort in the eye, erythema of the eyelids, conjunctivitis, symptoms of allergic eye damage, superficial punctate keratitis, eyelid edema, lacrimation, asthenopia, inflammation in the moisture of the anterior chamber, blepharitis.

Undesirable side reactions from systems and organs registered with tafluprost monotherapy, which are potentially capable of manifesting themselves with the use of Tapticom:

• organ of vision: loss of visual acuity, excessive pigmentation of the iris, pigmentation of the eyelids, discharge from the eyes, edema of the conjunctiva, opalescence of moisture in the anterior chamber of the eye, pigmentation of the conjunctiva, allergic conjunctivitis, conjunctival follicles, iritis / uveitis, deepening of the eyelid fold;
• skin and subcutaneous tissues: hypertrichosis of the eyelids;
• respiratory system: exacerbation of asthma, shortness of breath.

Undesirable side reactions from systems and organs registered with timolol monotherapy, which can potentially manifest themselves when using Tapticom:

• immune system: hypersensitivity reactions, including angioedema, urticaria, local or generalized skin rash, anaphylaxis, pruritus;
• metabolism and nutrition: hypoglycemia;
• psyche: insomnia, depression, nightmares, nervousness, memory loss;
• nervous system: dizziness, paresthesia, syncope, increased symptoms of myasthenia gravis, acute disturbance of the blood supply to the brain, cerebral ischemia;
• organ of vision: decreased sensitivity of the cornea, lacrimation, keratitis, impaired visual acuity (including refractive changes, sometimes after the cancellation of miotic treatment), diplopia, ptosis, detachment of the choroid after fistulizing antiglaucomatous operations, erosion of the cornea;
• organ of hearing and balance: tinnitus;
• cardiovascular system: chest pain, bradycardia, palpitations, arrhythmia, edema, heart failure, congestive heart failure, heart block, AV block, cardiac arrest, lower blood pressure, intermittent claudication, Raynaud's phenomenon, hypothermia of the hands and feet;
• respiratory system: shortness of breath, respiratory failure, bronchospasm (especially in patients with a history of bronchospastic disease), cough;
• digestive system: nausea, diarrhea, dyspepsia, dryness of the oral mucosa, abdominal pain, dysgeusia, vomiting;
• skin and subcutaneous fat: alopecia, skin rash, psoriasis-like rash / exacerbation of psoriasis;
• musculoskeletal system: myalgia, systemic lupus erythematosus, arthropathy;
• reproductive system and mammary gland: decreased libido, Peyronie's disease, sexual dysfunction;
• general disorders: asthenia and / or increased fatigue, thirst.

Very rarely, there have been reports of corneal calcification with serious damage in some patients as a result of the instillation of phosphate-containing eye drops.

Overdose

No cases of Tapticom overdose have been reported. When the solution is instilled into the conjunctival sac, intoxication is unlikely.

There have been reports of an unintentional significant excess of the dose of timolol, leading to the development of the following side effects similar to those with systemic use of β-blockers: dizziness, headache, shortness of breath, bradycardia, bronchospasm and cardiac arrest.

If signs of an overdose appear after instillation of eye drops with Tapticom, it is recommended, if necessary, to carry out symptomatic and supportive treatment. Excretion of timolol by hemodialysis is slowed down.

special instructions

Special instructions for using Tapticom:

• the development of systemic effects: the absorption of tafluprost and timolol, like other ophthalmic drugs, occurs systemically. The presence of a β-adrenergic component in Tapticom may contribute to the development of the same undesirable effects on the part of the cardiovascular and respiratory systems, as with the use of systemic β-blockers. The incidence of these reactions after instillation of eye drops is lower than as a result of systemic use. In addition, the systemic absorption of the solution can be reduced by temporary short-term finger pressing of the nasolacrimal canals or by closing the eyelids for 2 minutes after instillation, enhancing the local action of the solution;
• cardiac dysfunction: patients with arterial hypotension and cardiovascular pathologies, such as Prinzmetal's angina, coronary artery disease, heart failure, require a thorough assessment of the need for therapy with β-blockers and an analysis of the possibility of using ophthalmic drugs of other groups. It is necessary to monitor such patients in order to timely diagnose the deterioration of the condition and the development of unwanted adverse reactions. The negative effect of β-blockers on the rate of impulse conduction should be taken into account when using Tapticom to treat patients with AV block of I degree;
• vascular pathologies: the drug is used with caution in the treatment of patients with severe peripheral circulation disorders, for example, severe forms of Raynaud's disease / syndrome;
• diseases of the respiratory system: some β-blockers in ophthalmology can increase the likelihood of developing side effects from the respiratory system, up to a lethal outcome as a result of bronchospasm in patients with bronchial asthma. For mild / moderate COPD, Tapticum is prescribed with caution and only if the expected benefit from therapy outweighs the potential risk;
• diabetes mellitus, hypoglycemia: β-blockers are used with caution to treat patients prone to spontaneous hypoglycemia, or with a labile course of diabetes mellitus, since they are able to mask the symptoms of acute hypoglycemia;
• hyperthyroidism: β-blockers are used with caution in the treatment of patients with hyperthyroidism, since they can mask the signs of hyperthyroidism. Abrupt withdrawal of β-blockers can worsen the symptoms of the disease;
• pathology of the cornea: instillation of β-blockers can cause the development of dry eye syndrome. Ophthalmic preparations containing timolol are prescribed with caution for the treatment of patients with corneal diseases;
• combination with other β-blockers: in patients already receiving a systemic β-blocker, the use of timolol can increase the effect on intraocular pressure or the known effects of systemic blockade of β-adrenergic receptors. The condition of such patients should be carefully monitored. It is not recommended to use two local β-blockers simultaneously;
• Angle-closure glaucoma: The primary treatment goal for patients with angle-closure glaucoma is to open the anterior chamber angle of the eye, which requires constriction of the pupil with a miotic drug. The effect of timolol on the pupil is minimal or completely absent. Therefore, when it is used to reduce IOP in angle-closure glaucoma, it is necessary to use timolol not as monotherapy, but in combination with a miotic;
• allergic reactions of immediate type: β-blockers in patients with a history of atopy or severe anaphylactic reaction to a number of allergens can cause a stronger response to their repeated reception and stop the reaction to standard doses of epinephrine used to treat anaphylaxis;
• detachment of the choroid: there have been reports of ciliochoroidal detachment during the instillation of drugs that suppress the production of aqueous humor in the eye chambers (timolol, acetazolamide), after fistulizing surgery;
• general anesthesia: β-blockers in eye drops are capable of blocking the action of systemic β-adrenergic receptor agonists such as epinephrine. When planning surgical operations requiring pain relief, the anesthesiologist should be informed about the use of timolol by the patient;
• external changes: before the start of the course, the patient should be informed about the likelihood of excessive eyelash growth, increased pigmentation of the eyelid skin and iris associated with the instillation of tafluprost. Some of these transformations can be permanent, resulting in a difference in the appearance of the eyes if only one of them was treated. The pigmentation of the iris changes gradually, remaining unnoticeable for several months. Eye color predominantly changes in patients with mixed-colored irises (blue-brown, taupe, tan, or green-brown). Single eye therapy can cause persistent heterochromia.

Failure to comply with the storage rules of Tapticom can lead to bacterial contamination of eye drops, as a result of which bacterial infections of the organ of vision may develop, potentially dangerous with visual impairment or loss.

Influence on the ability to drive vehicles and complex mechanisms

The effect of the agent on a person's ability to drive a car and work with complex mechanisms has not been deliberately studied. Like any other ophthalmic drugs, Tapticom can cause short-term blurred vision. After instillation, it is necessary to refrain from performing types of work that require quick psychomotor reactions and increased concentration of attention, until visual function is restored.

Application during pregnancy and lactation

There is no adequate data on the effect of Tapticom on pregnancy.

Women with preserved reproductive function should use effective contraceptives during therapy with an ophthalmic drug.

Taptic is prescribed during pregnancy only if there are no other ways to lower IOP, when the potential benefit to the mother outweighs the possible risk to the fetus.

Information on the effect of the active components of Tapticom on pregnancy:

• tafluprost: there are no adequate data on the use in pregnant women; an adverse pharmacological effect on the course of pregnancy or the development of the fetus / newborn is allowed. Based on the results of animal studies, the reproductive toxicity of the substance has been established, at the same time, it is not known whether there is a potential risk of its use in humans;
• timolol: there are no adequate data on the use in pregnant women.

According to epidemiological studies, as a result of the intake of β-blockers inside, systemic pathologies of fetal development were not found, but there was a risk of slowing down its intrauterine development. In addition, if β-adrenergic blockers were prescribed before childbirth, such clinical manifestations and signs of β-adrenoreceptor blockade as hypotension, bradycardia, respiratory disorders, hypoglycemia were observed in newborns. The use of Tapticom before delivery requires careful monitoring of the condition of the newborn during the first days of life.

Information on the effect of the active components of Tapticom on breastfeeding:

• tafluprost: there are no data on the excretion of a substance or its metabolites in human breast milk. According to the available results of toxicological studies, the possibility of penetration of tafluprost and its metabolites into the breast milk of animals is not excluded. At the same time, it is unlikely that tafluprost in the composition of eye drops, instilled in the recommended therapeutic doses, is able to be excreted into breast milk in an amount sufficient for the development of clinical symptoms in an infant;
• timolol: β-blockers are known to be secreted during lactation in breast milk. At the same time, it is unlikely that timolol in the composition of eye drops in recommended therapeutic doses is able to be excreted into breast milk in an amount sufficient for the development of symptoms of β-adrenergic receptor blockade in an infant.

If a nursing woman requires Tapticom therapy, as a precaution, she needs to interrupt or stop breastfeeding.

There is no information on the effect of Tapticom on human reproductive function.

Pediatric use

The use of an ophthalmic drug in pediatrics is contraindicated. There is no data on the safety and efficacy of the clinical use of Tapticom in children and adolescents under 18 years of age.

With impaired renal function

The effect of Tapticom therapy on patients with impaired renal function has not been studied, which requires caution when prescribing it to patients in this clinical group.

For violations of liver function

The effect of Tapticom therapy on patients with liver failure has not been studied, which requires caution when prescribing it to patients in this clinical group.

Use in the elderly

No dose adjustment of Tapticom is required in elderly patients.

Drug interactions

The pharmacological interaction of Tapticom with other drugs / substances has not been studied.

There is a possibility of a decrease in blood pressure and / or the development of clinically pronounced bradycardia with the simultaneous use of ophthalmic drugs, including β-blockers, with the systemic use of other β-blockers, BMCC (slow calcium channel blockers), cardiac glycosides, antiarrhythmic drugs (incl. amiodarone), guanethidine, parasympathomimetics.

With oral administration of β-blockers, rebound arterial hypertension may increase, which develops as a result of the withdrawal of clonidine.

There is evidence that with the simultaneous use of inhibitors of the isoenzyme CYP2D6, such as quinidine, fluoxetine, paroxetine, with timolol, the systemic effect of a β-blocker increased, which was manifested by a decrease in heart rate and depression.

In some cases, the simultaneous use of adrenaline (epinephrine) with ophthalmic preparations containing a β-blocker caused mydriasis (dilation of the pupil).

Analogs

Analogs of Tapticom are Ganfort, Dorzitim, Dorzopt Plus, Kombigan, Kosopt, Ksalakom, Lanotan, Latamed, DuoTrav, Duoprost, Ksalatan, etc.

Terms and conditions of storage

Store out of the reach of children at a temperature of 2 to 8 ° C.

The shelf life is 3 years.

After opening the package with the dropper tube, the eye drops are stored in the original secondary packaging (package), protected from light, at a temperature not exceeding 25 ° C. The drug should be used within 4 weeks.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Tapticom

Ophthalmologists appreciate the benefits of a fixed combination of synthetic prostaglandin F _2α analogand a non-selective β-blocker in Tapticom. This complex allows you to reduce the frequency of application of drops, to increase the hypotensive efficacy of the solution due to the absence of the effect of preservatives, which also improves the tolerability of the drug. The washout effect associated with insufficient time interval between instillations is eliminated. The therapy regimen is simplified, which contributes to adherence to the dosage regimen and, as a result, stabilizes the IOP. In addition, the hypotensive effect of timolol at night is sharply reduced due to the natural decrease in the production of intraocular fluid, but prostaglandins, acting around the clock, lower the level of IOP, increasing the uveoscleral outflow. Prostaglandin analogs also reduce the risk of side effects associated with β-blockers by naturally diluting them.

Reviews of Tapticom from patients are mostly positive in terms of its therapeutic efficacy, ease of use and the absence of adverse reactions. Only the assessment of the cost of eye drops is ambiguous, which is characterized in the range from acceptable to expensive.

The price of Tapticom in pharmacies

Approximate price for Tapticom, eye drops 0.0015% + 0.5%, 0.3 ml each in a dropper tube, for 30 pcs. in the package ranges from 994 to 1076 rubles.

Tapticom: prices in online pharmacies

Drug name Price Pharmacy

Tapticom 0.0015% + 0.5% eye drops 0.3 ml 30 pcs. RUB 852 Buy

Tapticom eye drops 0.0015% + 0.5% tube-cap. 0.3ml 30 pcs. RUB 1006 Buy

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!